Fair Value Measurements - Summary of Change in the Fair Value (Detail)	12 Months Ended
	Dec. 31, 2021 USD ($)
Public Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Transfer of Public, Private Warrants to Level	$ (4,691,850)
Private Placement Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Transfer of Public, Private Warrants to Level	(171,570)
Over-Allotment Option [Member] \| Public Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Issuance of Public and Private Placement Warrants - over-allotment	291,850
Over-Allotment Option [Member] \| Private Placement Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Issuance of Public and Private Placement Warrants - over-allotment	5,840
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative warrant liabilities at January 8, 2021 (inception)	0
Fair Value, Inputs, Level 3 [Member] \| Public And Private Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Issuance of Public and Private Placement Warrants	5,229,200
Change in fair value of derivative warrant liabilities	(663,470)
Derivative warrant liabilities at at December 31, 2021	$ 0

European Biotech Acquisition Corp. 10-K